Alpha Omega Technology, Inc.; Denial Without Prejudice of Food Additive Petition, 15986 [2011-6623]
Download as PDF
15986
Federal Register / Vol. 76, No. 55 / Tuesday, March 22, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–1990–F–0390] (Formerly
Docket No. 90F–0074)
Alpha Omega Technology, Inc.; Denial
Without Prejudice of Food Additive
Petition
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is denying a food
additive petition (FAP 0M4181)
proposing that the food additive
regulations be amended to provide for
the safe use of a source of irradiation to
treat shellfish and finfish.
DATES: This order is effective June 20,
2011; except as to any provisions that
may be stayed by the filing of proper
objections. Submit either electronic or
written objections and requests for a
hearing by April 21, 2011.
ADDRESSES: You may submit either
electronic or written objections and
requests for a hearing, identified by
FDA–1990–F–0390, by any of the
following methods:
SUMMARY:
Electronic Submissions
Submit electronic objections in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
srobinson on DSKHWCL6B1PROD with NOTICES
Written Submissions
Submit written objections in the
following ways:
• FAX: 301–827–6870.
• Mail/Hand delivery/Courier (for
paper, disk, or CD–ROM submissions):
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Richard E. Bonnette, Center for Food
Safety and Applied Nutrition (HFS–
255), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740–3835, 301–436–1235.
SUPPLEMENTARY INFORMATION: In a notice
published in the Federal Register of
March 15, 1990 (55 FR 9772), FDA
announced that a food additive petition
(FAP 0M4181) had been filed by Alpha
Omega Technology, Inc., 1279 Route 46
East, Parsippany, NJ 07054. The petition
proposed to amend the food additive
regulations in § 179.26 Ionizing
radiation for the treatment of food (21
CFR 179.26) to provide for the safe use
VerDate Mar<15>2010
17:11 Mar 21, 2011
Jkt 223001
of a source of irradiation to treat finfish
and shellfish.
For any food additive petition, the
burden is on the petitioner to submit to
FDA data and information that are
adequate for the Agency to determine
that the proposed use of the additive
under the specified conditions of use is
safe (21 U.S.C. 348(c)(3)(A); 21 CFR
171.1). Alpha Omega Technology, Inc.,
was informed of significant deficiencies
in its petition by letters from FDA dated
May 28, 1992, September 15, 1993,
February 10, 1999, July 20, 2004, March
19, 2009, and May 22, 2009. The
deficiencies related primarily to the
possibility of Clostridium botulinum
outgrowth in packaged products,
especially where the normal growth
pattern of typical spoilage organisms
could be changed by irradiation, thus
reducing perception of spoilage.
FDA noted that the data provided in
the petition indicated that there was
very little margin of safety with regard
to the concern for C. botulinum
outgrowth and toxin elaboration,
particularly in irradiated fish stored at
temperatures between 46 and 50 degrees
Fahrenheit. FDA therefore requested
data demonstrating that products
irradiated at the maximum dose
requested and subjected to some
temperature abuse would show
evidence of spoilage before showing
evidence of toxicity.
Alpha Omega Technology, Inc., has
been unresponsive to these requests,
and other efforts to contact the
petitioner regarding the petition have
not been successful. The petitioner has
not provided sufficient data and
information for the Agency to conclude
that the proposed use of the food
additive is safe in accordance with
section 409 of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 348). Consequently, FDA is
denying the petition without prejudice
to a future filing (21 U.S.C. 348(c)(1)(B),
21 CFR 171.100(a)).
This order is effective as shown in the
DATES section of this document; except
as to any provisions that may be stayed
by the filing of proper objections. Any
person who will be adversely affected
by this order may file with the Division
of Dockets Management (see ADDRESSES)
either electronic or written objections.
Each objection shall be separately
numbered, and each numbered
objection shall specify with particularity
the provisions of the regulation to
which objection is made and the
grounds for the objection. Each
numbered objection on which a hearing
is requested shall specifically so state.
Failure to request a hearing for any
particular objection shall constitute a
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
waiver of the right to a hearing on that
objection. Each numbered objection for
which a hearing is requested shall
include a detailed description and
analysis of the specific factual
information intended to be presented in
support of the objection in the event
that a hearing is held. Failure to include
such a description and analysis for any
particular objection shall constitute a
waiver of the right to a hearing on the
objection. It is only necessary to send
one set of documents. It is no longer
necessary to send three copies of all
documents. Identify documents with the
docket number found in brackets in the
heading of this document. Any
objections received in response to the
order may be seen in the Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
FDA will publish notice of the
objections that the Agency has received
or lack thereof in the Federal Register.
Dated: March 15, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–6623 Filed 3–21–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Food and Drug Administration/Xavier
University Global Medical Device
Conference
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public conference.
The Food and Drug
Administration (FDA) Cincinnati
District, in co-sponsorship with Xavier
University, is announcing a public
conference entitled ‘‘FDA/Xavier
University Global Medical Device
Conference.’’ This 3-day public
conference includes presentations from
key FDA officials and industry experts.
The public conference has three
separate tracks of interest for quality,
regulatory affairs, and clinical research
professionals, and is intended for
companies of all sizes and employees at
all levels.
Dates and Times: The public
conference will be held on May 4, 2011,
from 8:30 a.m. to 5 p.m.; May 5, 2011,
from 8:30 a.m. to 5 p.m.; and May 6,
2011, from 8:30 a.m. to 1 p.m.
Location: The public conference will
be held on the campus of Xavier
University, 3800 Victory Pkwy.,
SUMMARY:
E:\FR\FM\22MRN1.SGM
22MRN1
Agencies
[Federal Register Volume 76, Number 55 (Tuesday, March 22, 2011)]
[Notices]
[Page 15986]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-6623]
[[Page 15986]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-1990-F-0390] (Formerly Docket No. 90F-0074)
Alpha Omega Technology, Inc.; Denial Without Prejudice of Food
Additive Petition
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is denying a food
additive petition (FAP 0M4181) proposing that the food additive
regulations be amended to provide for the safe use of a source of
irradiation to treat shellfish and finfish.
DATES: This order is effective June 20, 2011; except as to any
provisions that may be stayed by the filing of proper objections.
Submit either electronic or written objections and requests for a
hearing by April 21, 2011.
ADDRESSES: You may submit either electronic or written objections and
requests for a hearing, identified by FDA-1990-F-0390, by any of the
following methods:
Electronic Submissions
Submit electronic objections in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Written Submissions
Submit written objections in the following ways:
FAX: 301-827-6870.
Mail/Hand delivery/Courier (for paper, disk, or CD-ROM
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Richard E. Bonnette, Center for Food
Safety and Applied Nutrition (HFS-255), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park, MD 20740-3835, 301-436-1235.
SUPPLEMENTARY INFORMATION: In a notice published in the Federal
Register of March 15, 1990 (55 FR 9772), FDA announced that a food
additive petition (FAP 0M4181) had been filed by Alpha Omega
Technology, Inc., 1279 Route 46 East, Parsippany, NJ 07054. The
petition proposed to amend the food additive regulations in Sec.
179.26 Ionizing radiation for the treatment of food (21 CFR 179.26) to
provide for the safe use of a source of irradiation to treat finfish
and shellfish.
For any food additive petition, the burden is on the petitioner to
submit to FDA data and information that are adequate for the Agency to
determine that the proposed use of the additive under the specified
conditions of use is safe (21 U.S.C. 348(c)(3)(A); 21 CFR 171.1). Alpha
Omega Technology, Inc., was informed of significant deficiencies in its
petition by letters from FDA dated May 28, 1992, September 15, 1993,
February 10, 1999, July 20, 2004, March 19, 2009, and May 22, 2009. The
deficiencies related primarily to the possibility of Clostridium
botulinum outgrowth in packaged products, especially where the normal
growth pattern of typical spoilage organisms could be changed by
irradiation, thus reducing perception of spoilage.
FDA noted that the data provided in the petition indicated that
there was very little margin of safety with regard to the concern for
C. botulinum outgrowth and toxin elaboration, particularly in
irradiated fish stored at temperatures between 46 and 50 degrees
Fahrenheit. FDA therefore requested data demonstrating that products
irradiated at the maximum dose requested and subjected to some
temperature abuse would show evidence of spoilage before showing
evidence of toxicity.
Alpha Omega Technology, Inc., has been unresponsive to these
requests, and other efforts to contact the petitioner regarding the
petition have not been successful. The petitioner has not provided
sufficient data and information for the Agency to conclude that the
proposed use of the food additive is safe in accordance with section
409 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21
U.S.C. 348). Consequently, FDA is denying the petition without
prejudice to a future filing (21 U.S.C. 348(c)(1)(B), 21 CFR
171.100(a)).
This order is effective as shown in the DATES section of this
document; except as to any provisions that may be stayed by the filing
of proper objections. Any person who will be adversely affected by this
order may file with the Division of Dockets Management (see ADDRESSES)
either electronic or written objections. Each objection shall be
separately numbered, and each numbered objection shall specify with
particularity the provisions of the regulation to which objection is
made and the grounds for the objection. Each numbered objection on
which a hearing is requested shall specifically so state. Failure to
request a hearing for any particular objection shall constitute a
waiver of the right to a hearing on that objection. Each numbered
objection for which a hearing is requested shall include a detailed
description and analysis of the specific factual information intended
to be presented in support of the objection in the event that a hearing
is held. Failure to include such a description and analysis for any
particular objection shall constitute a waiver of the right to a
hearing on the objection. It is only necessary to send one set of
documents. It is no longer necessary to send three copies of all
documents. Identify documents with the docket number found in brackets
in the heading of this document. Any objections received in response to
the order may be seen in the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday. FDA will publish notice of the
objections that the Agency has received or lack thereof in the Federal
Register.
Dated: March 15, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-6623 Filed 3-21-11; 8:45 am]
BILLING CODE 4160-01-P